the world’s first CRISPR-based therapy
2023 marked a historic year in the field of genetic medicine with the UK’s approval of Casgevy, the world’s first CRISPR-based therapy, another biotech breakthrough. Developed by Vertex Pharmaceuticals and CRISPR Therapeutics, Casgevy (exa-cel) represents a landmark in the application of CRISPR gene-editing technology for treating inherited blood disorders such as sickle cell disease and beta-thalassemia. This approval by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, followed by the U.S. Food and Drug Administration (FDA), signifies a significant breakthrough in curative medicine​​​​​​​​.